Supernus Pharmaceuticals Inc. (SUPN) Jumps 5.53% on January 22

Equities Staff |

Supernus Pharmaceuticals Inc. (SUPN) was among the biggest gainers on the Russell 2000 for Friday January 22 as the stock popped 5.53% to $12.40, representing a gain of $0.65 per share. Some 346,645 shares traded hands on 3,204 trades, compared with an average daily volume of 841,367 shares out of a total float of 48.92 million. The stock opened at $12.02 and traded with an intraday range of $12.47 to $11.75.

After today's gains, Supernus Pharmaceuticals Inc. reached a market cap of $606.65 million. Supernus Pharmaceuticals Inc. has had a trading range between $23.30 and $8.20 over the last year, and it had a 50-day SMA of $14.34 and a 200-day SMA of $15.91.

The stock has a P/E Ratio of 36.7.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders.

Supernus Pharmaceuticals Inc. is based out of Rockville, MD and has some 309 employees. Its CEO is Jack Khattar.

For a complete fundamental analysis analysis of Supernus Pharmaceuticals Inc., check out’s Stock Valuation Analysis report for SUPN. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Propanc Health Group Corp

Propanc Health Group Corp is an early stage healthcare company. It is engaged in developing new cancer treatments for patients, suffering from pancreatic and colorectal cancer.

Private Markets

Ozobot by Evollve Inc

Ozobot is a world leader in compact super intelligent robots that entertain and educate through fun interactive gaming.


Autonomous security robots providing advanced detection capabilities at $7 per hour - aiming to define the future of security. Help #StopTheViolence.